Keryx Biopharmaceuticals (NASDAQ:KERX) has been given an average recommendation of “Hold” by the twelve ratings firms that are currently covering the firm. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $8.02.
Several analysts have recently weighed in on KERX shares. Maxim Group reiterated a “buy” rating and issued a $7.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Friday, March 3rd. Citigroup Inc upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “neutral” rating and set a $7.00 price objective for the company in a research note on Wednesday, January 11th.
TRADEMARK VIOLATION NOTICE: This report was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/04/21/keryx-biopharmaceuticals-kerx-receives-consensus-rating-of-hold-from-brokerages-updated.html.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 2.90% during midday trading on Friday, hitting $5.69. 632,024 shares of the company’s stock traded hands. The company has a 50 day moving average price of $5.63 and a 200 day moving average price of $5.50. Keryx Biopharmaceuticals has a 1-year low of $4.03 and a 1-year high of $7.80. The firm’s market capitalization is $612.63 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.07. Keryx Biopharmaceuticals had a negative return on equity of 270.26% and a negative net margin of 584.76%. The firm had revenue of $9.53 million for the quarter, compared to the consensus estimate of $9.65 million. During the same quarter in the previous year, the business posted ($0.36) EPS. The firm’s revenue for the quarter was up 64.9% compared to the same quarter last year. Equities analysts anticipate that Keryx Biopharmaceuticals will post ($0.67) earnings per share for the current year.
In related news, General Counsel Brian Adams sold 6,984 shares of the business’s stock in a transaction dated Monday, January 30th. The shares were sold at an average price of $4.65, for a total value of $32,475.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Greg Madison sold 18,248 shares of the business’s stock in a transaction dated Monday, January 30th. The stock was sold at an average price of $4.65, for a total transaction of $84,853.20. The disclosure for this sale can be found here. Insiders have sold a total of 37,750 shares of company stock worth $179,579 over the last ninety days. Insiders own 3.08% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Green Square Capital LLC acquired a new stake in Keryx Biopharmaceuticals during the third quarter valued at approximately $135,000. Lincoln Capital Corp acquired a new stake in Keryx Biopharmaceuticals during the fourth quarter valued at approximately $158,000. Creative Planning increased its stake in Keryx Biopharmaceuticals by 19.5% in the third quarter. Creative Planning now owns 36,789 shares of the biopharmaceutical company’s stock valued at $195,000 after buying an additional 6,000 shares during the period. Advisor Group Inc. increased its stake in Keryx Biopharmaceuticals by 15.9% in the third quarter. Advisor Group Inc. now owns 38,055 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 5,225 shares during the period. Finally, Marco Investment Management LLC increased its stake in Keryx Biopharmaceuticals by 6.5% in the third quarter. Marco Investment Management LLC now owns 49,350 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 3,000 shares during the period. 61.74% of the stock is currently owned by institutional investors and hedge funds.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.